Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Queensland Health
Baxter
Medtronic
Fish and Richardson

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,829,320

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,829,320
Title:Asparaginases
Abstract: The invention relates to new asparaginases having improved properties, preferably improved thermotolerance, such as improved activity at high temperatures and/or improved thermostability. The invention also relates to DNA sequences encoding such improved asparaginases, their production in a recombinant host cell, as well as methods of using the asparaginases, in particular for reduction of acrylamide in foods. The invention furthermore relates to methods of generating and preparing asparaginase variants having improved properties.
Inventor(s): Matsui; Tomoko (Chiba, JP), Friis; Esben Peter (Herlev, DK), Yamagishi; Akihiko (Tokyo, JP)
Assignee: Novozymes A/S (Bagsvaerd, DK)
Application Number:12/613,983
Patent Claims:1. A polypeptide which: (a) has asparaginase activity; (b) has at least 90% identity to amino acids 80 to 378 of SEQ ID NO: 1 and comprises an amino acid difference compared to SEQ ID NO: 1 at a position corresponding to any one of positions 54, 57, 260, 262, 307, 323, 327, 349, 351 and/or 353 in SEQ ID NO: 1; and (c) shows a residual asparaginase activity after heat treatment of at least 50% of the asparaginase activity without heat treatment, where heat treatment is incubation at pH 6 at a temperature of at least 64.degree. C. for 20 minutes.

2. The polypeptide of claim 1, which comprises at least one of the following substitutions: 54I, 57L, 260K, 262D, 307A/D/E, 323R, 327V, 349Q, 351A and/or 353I.

3. The polypeptide of claim 1, which comprises at least one of the following substitutions: 54I, 57L, 260K, 262D, 307A, 323R, 327V, 349Q, 351A and/or 353I.

4. The polypeptide of claim 1, which comprises at least one of the following substitutions: 323R, 327V, 349Q, 351A and/or 353I.

5. The polypeptide of claim 1, which shows a residual asparaginase activity after heat treatment of at least 60% of the asparaginase activity without heat treatment.

6. The polypeptide of claim 1, which shows a residual asparaginase activity after heat treatment of at least 70% of the asparaginase activity without heat treatment.

7. The polypeptide of claim 1, which shows a residual asparaginase activity after heat treatment of at least 80% of the asparaginase activity without heat treatment.

8. The polypeptide of claim 1, which shows a residual asparaginase activity after heat treatment of at least 90% of the asparaginase activity without heat treatment.

9. The polypeptide of claim 1, which shows a residual asparaginase activity after heat treatment, wherein heat treatment is for 30 minutes.

10. The polypeptide of claim 1, which shows a residual asparaginase activity after heat treatment, wherein heat treatment is for 40 minutes.

11. The polypeptide of claim 1, which further comprises 1-10 amino acid differences compared to SEQ ID NO: 1 at a position corresponding to any of positions 68-74, 82-86, 88, 93-96, 102, 107, 111, 113, 115, 137, 139, 164, 165, 172, 176, 184-186, 194, 196, 201, 206, 209, 212, 214, 215, 219, 220, 223, 224, 226, 228, 231, 235, 246, 249, 255, 264, 266, 271, 275, 278-288, 290, 299, 306, 309-321, 325, 328-342, 356-363, 365, 366 and/or 375 in SEQ ID NO: 1.

12. The polypeptide of claim 11, wherein the amino acid difference is a substitution.

13. The polypeptide of claim 12, which comprises a substitution in at least one of the following positions: 70, 83, 84, 86, 102, 137, 164, 196, 201, 228, 278, 283, 290, 312, 334, 336, 337, 366 and/or 375.

14. The polypeptide of claim 12, which comprises a substitution at position 70.

15. The polypeptide of claim 14, which further comprises a substitution in at least one of the following positions: 83, 84, 86, 102, 137, 164, 196, 201, 228, 278, 283, 290, 312, 334, 336, 337, 366 and/or 375.

16. The polypeptide of claim 12, which comprises at least one of the following substitutions: 69K/R, 70H/K/P/R/S, 72K/R, 82P, 83P/V, 84P/D, 85P, 86P, 88N, 93L, 94K, 95D, 96L, 102D, 107I, 111N, 113P, 115P, 137P/S/I, 139I, 164D/P, 165L, 172A, 176C, 184Y, 185N, 186A, 194E, 196E/I, 201P/Q, 206N, 209G, 212R, 214V, 215T, 219T, 220T, 223C/L/N, 224A, 228V, 231C, 235Q, 246C, 249I/LN, 255Q, 264L, 266L/K, 271C, 275N, 278H/K/P/Q/R, 279N/RN, 280D/E/P, 281D/E, 283C, 286L/N/R/V, 290E/LN, 299N, 306P, 311I/K/Q/R, 312N/R/V/Y, 317D/E, 318G, 320V, 321V, 325S, 328C, 331Q, 334F, 336C/G/L/P, 337F/I/K/Q/R, 356M, 361K/R, 363E/L/P/Q, 365P, 366P and/or 375T.

17. The polypeptide of claim 12, which comprises at least one of the following substitutions: 70H/K/S, 83V, 84D, 86P, 102D, 137S, 164D, 196I, 201Q, 228V, 278H/Q, 283C, 290V, 312Y, 334F, 336C/G/L, 337F/I, 366P and/or 375T.

18. The polypeptide of claim 12, which comprises one of the following substitutions: N70H, N70K or N70S.

19. The polypeptide of claim 12, which comprises the substitution N70K.

20. The polypeptide of claim 19, which further comprises one of the following substitutions: 323R, 327V, 349Q, 351A and/or 353I.

21. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of claim 1.

22. A nucleic acid construct comprising a nucleic acid sequence of claim 21 operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host.

23. A recombinant expression vector comprising the nucleic acid construct of claim 22.

24. A recombinant host cell comprising the nucleic acid construct of claim 22.

25. A method for producing a polypeptide, the method comprising: (a) cultivating the host cell of claim 24 to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide.

26. A method for producing a food product, comprising: (a) providing a food material; and (b) treating the food material with the polypeptide of claim 1.

27. The method of claim 26, wherein the food material is heated after step (b).

28. The method of claim 26, wherein the method is for reduction of acrylamide in the food product.

29. The method of claim 26, wherein the food product is a cereal based product; a vegetable based product; or a coffee based product.

30. The method of claim 26, wherein the food product is bread, pastry, cake, pretzels, bagels, cookies, gingerbread, gingercake, breakfast cereals, crispbread, a potato based product, french fries, potato chips, crisps, fabricated potato snacks or croquettes.

Summary for Patent:   Try a Free Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07103862Mar 09, 2007

Details for Patent 7,829,320

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial Novozymes A/S (Bagsvaerd, DK) 2027-03-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,829,320

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2008110513 Sep 18, 2008
United States of America 2009170157 Jul 02, 2009
United States of America 2010055726 Mar 04, 2010
United States of America 2010221385 Sep 02, 2010
United States of America 7666652 Feb 23, 2010
United States of America 7871806 Jan 18, 2011
Spain 2519466 Nov 07, 2014
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Healthtrust
McKesson
Fuji
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.